Charles R. Goulding and Aaron Rofe reveal how industry leaders like Eli Lilly, Johnson & Johnson, and Roche are going all-in ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Genie®, a leading innovator in garage door openers and home security products, proudly announces the release of its newest innovation: a residential linear actuator gate operator designed for ...

Ontario's financial services regulator, FSRA, has imposed an administrative penalty in the amount of $15,000 and a compliance order to cease and desist administering mortgages in Ontario on Razer ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

Eli Lilly and Purdue ... funding cuts to vital research. Lilly CEO Dave Ricks and Purdue University President Mung Chiang on May 9 announced a $250 million collaboration to build up pharmaceutical ...

Co-development of precision RNA therapeutics for inherited hearing loss treatmentSEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.